Literature DB >> 11841841

A DNA vaccine encoding the 42 kDa C-terminus of merozoite surface protein 1 of Plasmodium falciparum induces antibody, interferon-gamma and cytotoxic T cell responses in rhesus monkeys: immuno-stimulatory effects of granulocyte macrophage-colony stimulating factor.

Sanjai Kumar1, Francois Villinger, Miranda Oakley, Joao C Aguiar, Trevor R Jones, Richard C Hedstrom, Kalpana Gowda, John Chute, Anthony Stowers, David C Kaslow, Elaine K Thomas, John Tine, Dennis Klinman, Stephen L Hoffman, Walter W Weiss.   

Abstract

We have constructed a DNA plasmid vaccine encoding the C-terminal 42-kDa region of the merozoite surface protein 1 (pMSP1(42)) from the 3D7 strain of Plasmodium falciparum (Pf3D7). This plasmid expressed recombinant MSP1(42) after in vitro transfection in mouse VM92 cells. Rhesus monkeys immunized with pMSP1(42) produced antibodies reactive with Pf3D7 infected erythrocytes by IFAT, and by ELISA against yeast produced MSP1(19) (yMSP1(19)). Immunization also induced antigen specific T cell responses as measured by interferon-gamma production, and by classical CTL chromium release assays. In addition, immunization with pMSP1(42) primed animals for an enhanced antibody response to a subsequent boost with the recombinant yMSP1(19). We also evaluated Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as an adjuvant for pMSP1(42.) We tested both rhesus GM-CSF expressed from a DNA plasmid, and E. coli produced recombinant human GM-CSF. Plasmids encoding rhesus GM-CSF (prhGM-CSF) and human GM-CSF (phuGM-CSF) were constructed; these plasmids expressed bio-active recombinant GMCSF. Co-immunization with a mixture of prhGM-CSF and pMSP1(42) induced higher specific antibody responses after the first dose of plasmid, but after three doses of DNA monkeys immunized with or without prhGM-CSF had the same final antibody titers and T cell responses. In comparison, rhuGM-CSF protein did not lead to accelerated antibody production after the first DNA dose. However, antibody titers were maintained at a slightly higher level in monkeys receiving GM-CSF protein, and they had a higher response to boosting with recombinant MSP1(19). The GM-CSF plasmid or protein appears to be less potent as an adjuvant in rhesus monkeys than each is in mice, and more work is needed to determine if GM-CSF can be a useful adjuvant in DNA vaccination of primates.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11841841     DOI: 10.1016/s0165-2478(01)00316-9

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  11 in total

1.  Allele specificity of gamma interferon responses to the carboxyl-terminal region of Plasmodium falciparum merozoite surface protein 1 by Kenyan adults with naturally acquired immunity to malaria.

Authors:  Michele D Spring; Kiprotich Chelimo; Daniel J Tisch; Peter Odada Sumba; Rosemary Rochford; Carole A Long; James W Kazura; Ann M Moormann
Journal:  Infect Immun       Date:  2010-08-09       Impact factor: 3.441

2.  A bicistronic DNA vaccine containing apical membrane antigen 1 and merozoite surface protein 4/5 can prime humoral and cellular immune responses and partially protect mice against virulent Plasmodium chabaudi adami DS malaria.

Authors:  A Rainczuk; T Scorza; T W Spithill; P M Smooker
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

3.  Transcriptionally active PCR for antigen identification and vaccine development: in vitro genome-wide screening and in vivo immunogenicity.

Authors:  David P Regis; Carlota Dobaño; Paola Quiñones-Olson; Xiaowu Liang; Norma L Graber; Maureen E Stefaniak; Joseph J Campo; Daniel J Carucci; David A Roth; Huaping He; Philip L Felgner; Denise L Doolan
Journal:  Mol Biochem Parasitol       Date:  2007-11-22       Impact factor: 1.759

4.  CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine.

Authors:  Sanjai Kumar; Trevor R Jones; Miranda S Oakley; Hong Zheng; Shanmuga P Kuppusamy; Alem Taye; Arthur M Krieg; Anthony W Stowers; David C Kaslow; Stephen L Hoffman
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

5.  GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine.

Authors:  Lilin Lai; Dalma Vödrös; Pamela A Kozlowski; David C Montefiori; Robert L Wilson; Vicki L Akerstrom; Lakshmi Chennareddi; Tianwei Yu; Sunil Kannanganat; Lazarus Ofielu; Francois Villinger; Linda S Wyatt; Bernard Moss; Rama Rao Amara; Harriet L Robinson
Journal:  Virology       Date:  2007-08-14       Impact factor: 3.616

6.  Measuring the effects of an ever-changing environment on malaria control.

Authors:  Thomas F McCutchan; K Christiana Grim; Jun Li; Walter Weiss; Darmendar Rathore; Margery Sullivan; Thaddeus K Graczyk; Sanjai Kumar; Mike R Cranfield
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

7.  A nonhuman primate scrub typhus model: protective immune responses induced by pKarp47 DNA vaccination in cynomolgus macaques.

Authors:  Daniel H Paris; Suchismita Chattopadhyay; Ju Jiang; Pruksa Nawtaisong; John S Lee; Esterlina Tan; Eduardo Dela Cruz; Jasmin Burgos; Rodolfo Abalos; Stuart D Blacksell; Eric Lombardini; Gareth D Turner; Nicholas P J Day; Allen L Richards
Journal:  J Immunol       Date:  2015-01-19       Impact factor: 5.422

Review 8.  Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity.

Authors:  John J Suschak; James A Williams; Connie S Schmaljohn
Journal:  Hum Vaccin Immunother       Date:  2017-06-12       Impact factor: 3.452

9.  Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA.

Authors:  Thomas L Richie; Yupin Charoenvit; Ruobing Wang; Judith E Epstein; Richard C Hedstrom; Sanjai Kumar; Thomas C Luke; Daniel A Freilich; Joao C Aguiar; John B Sacci; Martha Sedegah; Ronald A Nosek; Patricia De La Vega; Mara P Berzins; Victoria F Majam; Esteban N Abot; Harini Ganeshan; Nancy O Richie; Jo Glenna Banania; Maria Fe B Baraceros; Tanya G Geter; Robin Mere; Lolita Bebris; Keith Limbach; Bradley W Hickey; David E Lanar; Jennifer Ng; Meng Shi; Peter M Hobart; Jon A Norman; Lorraine A Soisson; Michael R Hollingdale; William O Rogers; Denise L Doolan; Stephen L Hoffman
Journal:  Hum Vaccin Immunother       Date:  2012-11-01       Impact factor: 3.452

10.  DNA vaccines: designing strategies against parasitic infections.

Authors:  Catherine Ivory; Kris Chadee
Journal:  Genet Vaccines Ther       Date:  2004-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.